portrait
Research Projects Available
DPhil
- 2026 Raman Group: Pioneering Precision Medicine in Hypertrophic Cardiomyopathy: Advanced Imaging, Machine Learning, and Translational Research for Early Detection and Targeted Therapies — Radcliffe Department of Medicine
- 2026 Raman Group (MRC Enterprise iCase): Development of Cardiac Diffusion Tensor Imaging for Clinical Evaluation of Cardiomyopathies — Radcliffe Department of Medicine
MSc by Research
- Raman Group: Intergrating Multimodal Imaging, Genomics, and Clinical Data for Risk Stratification and Precision Therapy in Cardiomyopathies through Novel Artificial Intelligence Approaches — Radcliffe Department of Medicine
- Raman Group: Multi-Organ MRI Phenotyping for Risk Prediction in Heart Failure and Multisystem Diseases: Insights from Prospective Imaging Cohorts and UK Biobank — Radcliffe Department of Medicine
- Raman Group: AI-Enhanced ECG and Digital Twin Modelling for Early Diagnosis and Mechanistic Stratification in Cardiomyopathies — Radcliffe Department of Medicine
- Raman Group: Unravelling Mechanisms of Phenotypic Diversity in Hypertrophic Cardiomyopathy through Advanced Cardiac MRI and Patient-Specific Multi-Omic Modelling — Radcliffe Department of Medicine
- Raman Group: Enhancing Traditional and Photon-Counting CT for the Early Diagnosis and Phenotyping of Cardiomyopathies — Radcliffe Department of Medicine
Colleges
Websites
-
Sky news
Findings from the C-MORE - multiorgan MRI Study
-
BBC news
Findings from the C-MORE - multiorgan MRI Study
-
BBC world radio
Betty Raman presenting findings from the C-MORE study (8:20)
Betty Raman
MBBS DPhil FESC FRACP
- Assoc Professor of Cardiovascular Medicine
- NIHR South Central RRDN Cardiology Specialty Lead
- Hon. Consultant Cardiologist (Loc)
- Wellcome Career Development Award Fellow
- RDM Cardiovascular Medicine EDI Champion
Prof Betty Raman is a senior honorary consultant cardiologist specialising in advanced cardiovascular imaging (CMR and cardiac CT) and inherited and cardiomyopathic heart disease. She leads a translational research programme that bridges mechanistic discovery, clinical application, and innovation in drug development.
After completing her specialist cardiology training in Australia (FRACP), she joined the University of Oxford in 2015 to pursue a DPhil in hypertrophic cardiomyopathy, the leading cause of sudden cardiac death in young adults and athletes. Her doctoral work led to the development of a novel oxygen sensitive magnetic resonance method that detects myocardial hypoxia non-invasively and holds promise as an early biomarker of disease activity. This pioneering work has been recognised internationally through awards from the ESC, AHA, BSCMR, SCMR, and BCS.
Building on this foundation, she was awarded a British Heart Foundation Transition Fellowship (2020) and subsequently a Wellcome Career Development Award (2024) to advance a multidisciplinary research programme integrating imaging, genetics, energetics, and computational modelling. Her goal is to identify and validate early markers of disease progression in hypertrophic and related cardiomyopathies, enabling more precise risk prediction and supporting evaluation of emerging therapies.
During the COVID 19 pandemic, she led the C-MORE study, a large multicentre initiative that combined MRI, cardiopulmonary exercise testing, and cognitive assessments to characterise the long term multi organ consequences of COVID 19. This work helped shape understanding of post-viral cardiovascular and systemic recovery.
Her current research focuses on:
Early stage disease detection and monitoring in cardiomyopathies using next generation CMR including BOLD, DTI, spectroscopy, and radiomics.
Mechanistic biomarkers to support early phase and adaptive clinical trials.
Cross organ interactions in cardiometabolic disease, integrating heart, brain, liver, and renal imaging.
As a senior academic leader, she collaborates widely across academia, the NHS, and industry to translate advanced imaging into clinical and commercial impact. She actively welcomes scientific collaborators, students, and industrial partners interested in biomarker discovery, imaging enabled trial design, and AI based modelling for cardiovascular disease.
Recent publications
-
Subclinical Postpartum Renal Structure After Hypertensive Pregnancy Disorders.
Journal article
Cutler HR. et al, (2025), Hypertension
-
Correction to: Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases (Circ Res. (2025) 136 (1454-1475) DOI: 10.1161/CIRCRESAHA.125.325517)
Journal article
Devesa A. et al, (2025), Circulation Research, 137
-
Brain and muscle chemistry in myalgic encephalitis/chronic fatigue syndrome (ME/CFS) and long COVID: a 7T magnetic resonance spectroscopy study.
Journal article
Godlewska BR. et al, (2025), Mol Psychiatry
-
Cohort profile: characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19 - providing the evidence base for health care services (CONVALESCENCE) in the UK.
Journal article
Jamieson A. et al, (2025), BMJ Open, 15
-
Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases
Journal article
Devesa A. et al, (2025), Circulation Research, 136, 1454 - 1475
-
Post-Hospitalisation COVID-19 Rehabilitation (PHOSP-R): A randomised controlled trial of exercise-based rehabilitation.
Journal article
Daynes E. et al, (2025), Eur Respir J
-
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy.
Journal article
Tadros R. et al, (2025), Nat Genet
-
Multiparametric cardiovascular magnetic resonance evaluation of myocardial perfusion, oxygenation, and energetics in hypertrophic cardiomyopathy following cardiac myosin inhibitor therapy.
Journal article
Finnigan LEM. et al, (2025), Eur Heart J Cardiovasc Imaging, 26
-
Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk.
Journal article
Ashkir Z. et al, (2025), Eur Heart J Cardiovasc Imaging, 26, 218 - 228
-
GENETIC ASSOCIATION OF CLONAL HEMATOPOIESIS WITH NON-ISCHEMIC CARDIAC DISEASE AND ADVERSE REMODELING
Journal article
Morley A. et al, (2025), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 85, 330 - 330
-
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Journal article
Gharibzadeh S. et al, (2025), EClinicalMedicine, 79
-
Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis.
Journal article
Shiwani H. et al, (2024), J Am Coll Cardiol
-
1H and 31P MR Spectroscopy to Assess Muscle Mitochondrial Dysfunction in Long COVID
Journal article
Finnigan LEM. et al, (2024), Radiology, 313
-
1H and 31P MR Spectroscopy to Assess Muscle Mitochondrial Dysfunction in Long COVID.
Journal article
Finnigan LEM. et al, (2024), Radiology, 313
-
Effects of software on myocardial T1 measurements: a 3 T multicentre single vendor phantom study
Conference paper
Atkinson D. et al, (2024)
-
1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.
Journal article
Leavy OC. et al, (2024), ERJ Open Res, 10
-
Association between SARC-F status and long-term physical function after COVID-19 hospitalisation
Conference paper
Mills G. et al, (2024), EUROPEAN RESPIRATORY JOURNAL, 64
-
Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations (oct, awae332,2024)
Journal article
Rua C. et al, (2024), BRAIN, 148, e3 - e3
-
ABNORMAL SKELETAL METABOLISM BUT NOT CARDIAC DYSFUNCTION AS A CAUSE FOR FATIGUE POST COVID-19
Conference paper
Cassar MP. et al, (2023), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 81, 1397 - 1397
-
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization
Journal article
Taquet M. et al, (2023), NATURE MEDICINE
-
Efficacy and Tolerability of AXA1125, an Endogenous Metabolic Modulator Composition, in Fatigue-predominant Long COVID: A Randomized, Double-blind, Placebo-controlled Study
Conference paper
Finnigan L. et al, (2023), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 207
-
IMPAIRED STRESS MYOCARDIAL OXYGENATION PRECEDES CONTRACTILE ABNORMALITIES IN THREE MODELS OF CARDIAC HYPERTROPHY: INSIGHTS FROM A NOVEL OXYGEN SENSITIVE CARDIAC MAGNETIC RESONANCE APPROACH
Conference paper
Akhtar MA. et al, (2023), HEART, 109, A8 - A9
-
LIVER DISEASE ACTIVITY IS A SIGNIFICANT RISK FACTOR FOR CARDIOVASCULAR OUTCOMES -A PROSPECTIVE ANALYSIS OF 33,616 INDIVIDUALS FROM THE UK BIOBANK
Conference paper
Roca-Fernandez A. et al, (2023), GASTROENTEROLOGY, 164, S72 - S73
-
Subclinical Flow Inefficiencies in Non-Obstructive Hypertrophic Cardiomyopathy Subgroups Revealed by 4D Flow Cardiovascular Magnetic Resonance
Journal article
Pola K. et al, (2023), CIRCULATION, 148
-
ASSOCIATION OF MRI-DERIVED LIVER BIOMARKERS WITH CARDIOVASCULAR RISK FACTORS, OUTCOMES, AND ALL-CAUSE MORTALITY-A PROSPECTIVE ANALYSIS OF 33,616 INDIVIDUALS FROM THE UK BIOBANK COHORT
Conference paper
Roca-Fernandez A. et al, (2022), HEPATOLOGY, 76, S727 - S728
-
Cardiopulmonary Assessment of COVID-19 Survivors Stratified by Acute Disease Severity and Post-Acute Symptoms
Conference paper
Szekely Y. et al, (2022), CIRCULATION, 146
-
NOVEL INSIGHTS INTO DIMINISHED CARDIAC RESERVE IN HYPERTROPHIC CARDIOMYOPATHY FROM 4D FLOW CMR COMPONENT ANALYSIS
Conference paper
Ashkir Z. et al, (2022), HEART, 108, A3 - A4
-
Persistence of inflammatory and vascular damage mediators 5 months after acute COVID-19
Conference paper
Petousi N. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60